In the crude analysis of our study, decreased AD risk was found to be associated with monotherarpy with sulfonylurea; increased risk for AD was associated with combination therapy using non-sulfonylurea insulin secretagouge, and either monotherapy or combination with insulin. The gene discussed is INS; the disease is Alzheimer disease.